↓ Skip to main content

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the…

Overview of attention for article published in Journal of Clinical Oncology, August 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (97th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

news
4 news outlets
policy
1 policy source
patent
5 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
659 Dimensions

Readers on

mendeley
267 Mendeley
citeulike
2 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Published in
Journal of Clinical Oncology, August 2009
DOI 10.1200/jco.2008.20.5534
Pubmed ID
Authors

Joaquim Bellmunt, Christine Théodore, Tomasz Demkov, Boris Komyakov, Lisa Sengelov, Gedske Daugaard, Armelle Caty, Joan Carles, Agnieszka Jagiello-Gruszfeld, Oleg Karyakin, François-Michel Delgado, Patrick Hurteloup, Eric Winquist, Nassim Morsli, Yacine Salhi, Stéphane Culine, Hans von der Maase

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 267 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 2 <1%
United States 2 <1%
Portugal 1 <1%
Korea, Republic of 1 <1%
United Kingdom 1 <1%
Brazil 1 <1%
Spain 1 <1%
Denmark 1 <1%
Unknown 257 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 42 16%
Other 38 14%
Student > Ph. D. Student 29 11%
Student > Doctoral Student 22 8%
Student > Postgraduate 20 7%
Other 68 25%
Unknown 48 18%
Readers by discipline Count As %
Medicine and Dentistry 136 51%
Biochemistry, Genetics and Molecular Biology 22 8%
Agricultural and Biological Sciences 17 6%
Pharmacology, Toxicology and Pharmaceutical Science 11 4%
Economics, Econometrics and Finance 4 1%
Other 18 7%
Unknown 59 22%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 41. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2022.
All research outputs
#991,370
of 25,371,288 outputs
Outputs from Journal of Clinical Oncology
#2,398
of 22,043 outputs
Outputs of similar age
#2,791
of 121,073 outputs
Outputs of similar age from Journal of Clinical Oncology
#5
of 157 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,043 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,073 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 157 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.